-
Study aim
-
This study aims to compare the efficacy of extended-release (XR) and immediate-release (IR) metformin in controlling blood glucose levels among women with gestational diabetes mellitus (GDM). Adverse effects and tolerability will also be compared.
-
Design
-
Two-arm, parallel-group, open-label randomized controlled trial designed to compare the efficacy of two metformin formulations in women with gestational diabetes mellitus. Participants will be assigned to two treatment groups using block randomization with a 1:1 allocation ratio.
-
Settings and conduct
-
The study will be conducted at Ghaem Hospital, Mashhad, Iran. Eligible women with GDM will be randomly assigned to XR or IR metformin. Fasting and postprandial glucose levels, adverse effects, and the need for insulin therapy will be assessed.
-
Participants/Inclusion and exclusion criteria
-
Women aged 18–45 years with singleton pregnancies at 24–26 weeks of gestation, diagnosed with GDM by OGTT, will be enrolled after informed consent. Exclusion criteria include interacting medications, creatinine >1.2 mg/dL, metformin hypersensitivity, heart failure, myocardial infarction, moderate to severe pulmonary disease, and adrenal or pituitary insufficiency.
-
Intervention groups
-
Participants will receive either IR or XR metformin, starting at 500 mg with dinner. Doses will be adjusted according to the study protocol based on glycemic control. Blood glucose levels and adverse effects will be monitored in both groups.
-
Main outcome variables
-
Fasting blood glucose (FBG), one-hour postprandial blood glucose, and two-hour postprandial blood glucose levels.